Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda) and targeted therapies (e.g., Eisai’s Lenvima) are experiencing uptake. Some agents target specific biomarker-defined populations, such as MSI-H or dMMR, and others target all patients. The approval and uptake of these agents will result in a more-personalized approach to treating advanced endometrial carcinoma. Several agents are also being positioned for the untapped first-line setting (e.g., GSK/Tesaro’s dostarlimab, Karyopharm’s Xpovio, AstraZeneca’s Lynparza) and will contribute to robust market growth over the 2019-2029 forecast period.
- How large are the clinically and commercially relevant drug-treatable endometrial carcinoma populations, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as Keytruda and Lenvima, for endometrial carcinoma?
- Which pipeline products are poised to become options for the treatment of endometrial carcinoma, and what sales / uptake will they secure?
- What are the key drivers and constraints in the endometrial carcinoma market, and how will the major markets evolve over the ten-year forecast period?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists.
Epidemiology: Diagnosed incident of endometrial carcinoma by country, disease stage, and risk status.
Forecast: 10-year, annualized, drug- and regimen-level sales and patient share of key endometrial cancer therapies through 2029, segmented by brands / biosimilars / generics, disease stage, and country.
Emerging therapies: Phase III/PR: 5 drugs; coverage of select early-phase products.